Efficacy and Cost-Effectiveness of Vonoprazan-Amoxicillin Dual Therapy Versus Esomeprazole-Bismuth Quadruple Therapy for

Lihua Guo, Jiaxin Ge, Min Miao, Guimei Hu, Jinfeng Wen, Kefeng Hu, Guoliang Ye

Abstract read

In one paragraph

Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lihua GuoDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315020, China.ORCID 0000-0002-2434-1606

Jiaxin GeDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315020, China.

Min MiaoDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315020, China.

Guimei HuDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315020, China.

Jinfeng WenDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315020, China.

Kefeng HuDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315020, China.

Guoliang YeDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315020, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vonoprazan-amoxicillin (VA) dual therapy offers a simplified alternative; however, its efficacy and cost-effectiveness relative to bismuth-containing quadruple therapy (BQT) in treatment-naïve patients remain unclear. This study aimed to compare the eradication rate and cost-effectiveness between the two groups using a propensity score-matched analysis. This retrospective, single-center study used outpatient electronic medical records from January 2024 to November 2025. After propensity score matching (1:1), 212 patients received vonoprazan-amoxicillin dual therapy (VA), and 212 matched patients received esomeprazole-bismuth quadruple therapy (EBAC) for two weeks. Eradication rates and cost-effectiveness were compared. According to the intention-to-treat (ITT) analysis, eradication rates were 90.56% (95% CI 85.88-93.81%) in the VA group and 90.09% (95% CI 85.33-93.43%) in the EBAC group (

Indexed as

bismuth-containing quadruple therapycost-effectivenessdual therapyeradication rateHelicobacter pyloriprobabilistic sensitivity analysis

Identifiers

PMID42197391

DOI10.3390/microorganisms14051006

PMCPMC13210209

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.